Christian Kappeler

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet · 2014 · 1.6K citations · Full text

Medicine, Endocrinology, Oncology +11

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +8

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela et al. · New England Journal of Medicine · 2019 · 922 citations · Full text

Medicine, Oncology, Pharmacology +15

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology · 2015 · 816 citations

Medicine, Oncology, Pharmacotherapy +10

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Eric Van Cutsem, Erika Martinelli, Stefano Cascinu et al. · The Oncologist · 2018 · 143 citations · Full text

Medicine, Oncology, Pharmacology +15